This report reviews a new clinical trial comparing tendon grafts and muscle tendon grafts in ACL reconstruction and outlines regulatory implications for device selection and safety.
On February 11, 2026, ClinicalTrials.gov records describe a study under the cruciate ligament reconstruction indication. The sponsor is University Hospital Dubrava and the trial is listed as NCT07404046. The recruitment status is active, indicating that enrollment or screening is ongoing. The objective is to compare graft materials used in ACL reconstruction to inform material choices and surgical planning for regulators and clinicians alike.
What is the study about and who conducts it?
The trial compares tendon grafts with muscle tendon grafts from semitendinosus in ACL reconstruction. The sponsor is University Hospital Dubrava, and the ClinicalTrials.gov listing is NCT07404046. The status is recruiting, meaning patient enrollment is ongoing. The purpose is to inform graft selection and procedural planning for ACL reconstruction in clinical practice.
What exactly is being compared?
The comparison focuses on the source of graft material and its potential impact on surgical technique and outcomes. The record does not provide performance data or safety results at this time.
What are the regulatory implications for device selection and safety?
While no results are published yet, the record highlights an active evaluation of graft materials used in ACL reconstruction. Future findings may influence regulatory expectations for device labeling, risk disclosures, and post market surveillance related to graft devices. Manufacturers and regulators may monitor the evidence to support intended use statements and performance claims in subsequent regulatory submissions.
What claims may be affected?
Intended use and performance expectations for graft related devices could be updated as new data emerges on graft type performance, reinforcing the need for robust evidence in device related decision making.
Who should care about these findings?
Surgeons selecting graft material, device developers planning graft related products, and regulatory professionals tracking ACL protocols should follow this trial. The sponsor is University Hospital Dubrava and the ClinicalTrials.gov listing provides the public record. Transparent reporting will help stakeholders evaluate how graft choices may influence safety and device performance in real world use.
What about patient implications?
Patients may later benefit from improved graft selection guidance and clearer device performance information. Clinicians should monitor forthcoming results and align practice with new evidence and regulatory guidance.
What comes next and what safety considerations apply?
The current status is recruiting, and a timeline for results has not been announced. As data become available they will be assessed for consistency with safety standards and with regulatory expectations for labeling and post market reporting. The study demonstrates a careful comparison of graft materials in an environment that places mechanical demands on the reconstruction, underscoring the importance of evidence based device related decision making.
FAQ
- 1. What is the study about?
It compares tendon grafts and muscle tendon grafts from semitendinosus in ACL reconstruction. - 2. Who sponsors the study?
University Hospital Dubrava is listed as sponsor. - 3. Where can I find the study record?
The record is on ClinicalTrials.gov with the identifier NCT07404046.
Conclusion
This trial represents an early step in evaluating graft materials used for ACL reconstruction and informs the regulatory discourse around device labeling and safety. Stakeholders should track enrollment status and forthcoming results to guide practice and policy.
This information is intended for professional use. It is not legal advice. Consult a regulatory expert for formal guidance.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07404046?term=medical+device